By: Sarah Boseley and Nils Pratley


We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

It is the biggest and most powerful drug company on the planet. But Pfizer's global reach has not turned the world's third largest business into a benevolent giant, according to its critics. Instead, the vast multinational stands accused of blocking reforms to global drug pricing that would help lift impoverished countries out of disease and spur their development.

In this article Sarah Boseley and Nils Pratley describe how critics are asking increasingly urgent questions about Pfizer's attitude to those who need medicines in poor countries, saying that the company should take a lead in conceding a system of low prices in the developing world.

Critics also warn that the battle for drugs is no longer limited to AIDS, malaria, tuberculosis and similar infectious pandemics. Before long, the struggle will inevitably move on to the insidious and profitable diseases that affect millions in rich countries as well as poor, such as cancer.

Link to full Guardian article

Related topics